Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
TD Cowen analyst Phil Nadeau has maintained a Buy rating on Voyager Therapeutics (VYGR) stock, citing the company's strong financial position with $229 million in cash, ensuring operations until 2028. The promising Alzheimer’s pipeline, including assets VY7523 and VY1706, is progressing towards key milestones in 2026. Collaborations with Neurocrine Biosciences also indicate growth potential. Leerink Partners echoed this sentiment with a Buy rating and a $11.00 price target.
TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Phil Nadeau has given his Buy rating due to a combination of factors including Voyager Therapeutics’ strong financial position and promising pipeline developments. The company reported a solid cash position of $229 million, providing a financial runway until 2028, which supports its ongoing and future projects.
Voyager’s Alzheimer’s pipeline is showing significant progress with its wholly-owned assets, VY7523 and VY1706, advancing towards key milestones in 2026. Additionally, the collaboration with Neurocrine Biosciences on GBA1 and FXN programs is on track for Phase I initiation in 2026, indicating potential growth opportunities. These strategic advancements and partnerships underscore Voyager’s potential for future success, justifying the Buy rating.
In another report released today, Leerink Partners also maintained a Buy rating on the stock with a $11.00 price target.
